<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="129284">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01681576</url>
  </required_header>
  <id_info>
    <org_study_id>CLCZ696A2222</org_study_id>
    <nct_id>NCT01681576</nct_id>
  </id_info>
  <brief_title>Assessment of LCZ696 and Valsartan in Asian Patients With Salt-sensitive Hypertension</brief_title>
  <official_title>A Randomized, Double-blind, Crossover Study to Assess the Effects of LCZ696 and Valsartan in Asian Patients With Salt-sensitive Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Korea: Food and Drug Administration</authority>
    <authority>Taiwan: Department of Health</authority>
    <authority>Singapore: Health Sciences Authority</authority>
    <authority>Hong Kong: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effect of LCZ696 and valsartan on natriuresis, diuresis, and
      blood pressure in salt-sensitive Asian hypertensive patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
  <primary_outcome>
    <measure>Cumulative Sodium excretion (natriuresis)</measure>
    <time_frame>6 hour following the first dose of LCZ696 and valsartan</time_frame>
    <safety_issue>No</safety_issue>
    <description>Urine will be collected in fractions of 0 to 6 hours post-dose. From each fraction, a sample will be drawn for analysis of sodium</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative Sodium excretion (natriuresis)</measure>
    <time_frame>24 hour following the first dose of LCZ696 and valsartan</time_frame>
    <safety_issue>No</safety_issue>
    <description>Urine will be collected in fractions of 6 to 24 hours post-dose. From each fraction, a sample will be drawn for analysis of sodium</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>During 4 weeks treatment</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Summarized statistics on adverse events will be reported which will be categorized as total adverse events, serious adverse events and death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Sodium excretion (natriuresis)</measure>
    <time_frame>After 4 weeks of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Urine will be collected in fractions of 0 to 6 hours and 6 to 24 hours post-dose. From each fraction, a sample will be drawn for analysis of sodium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Volume (Diuresis)</measure>
    <time_frame>During 6 and 24 hours post first dose and after 4 weeks of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Urine will be collected and volume measured in fractions of 0 to 6 hours and 6 to 24 hours post-dose first and last dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of LCZ696   (AHU377, LBQ657, valsartan) and Valsartan: Observed maximum plasma concentration (Cmax) following drug administration</measure>
    <time_frame>Day 1 and day 28 of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood will be collected at intervals and plasma separated and analyzed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of LCZ696   (AHU377, LBQ657, valsartan) and Valsartan: Time to reach the maximum concentration after drug administration (Tmax)</measure>
    <time_frame>Day 1 and day 28 of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood will be collected at intervals and plasma separated and analyzed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of LCZ696   (AHU377, LBQ657, valsartan) and Valsartan:Area under the plasma concentration-time curve from time zero to 24 hours (AUC0-24 hours)</measure>
    <time_frame>Day 1 and day 28 of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood will be collected at intervals and plasma separated and analyzed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of LCZ696 and valsartan: Accumulation ratio between Day 28 and Day 1</measure>
    <time_frame>Day 1 and day 28 of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood will be collected at intervals and plasma separated and analyzed and the ratio AUC-24 hr(Day28) / AUC-24 hr(Day1) calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean seated  blood pressure following 4 weeks of treatment</measure>
    <time_frame>Day 1 and day 28 of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Seating BP (systolic blood pressure (msSBP) and diastolic blood pressure (msDBP))measurements will be performed at trough(immediately prior to dosing at the clinic). Arterial BP readings will be made with an automated BP device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean arterial pressure (MAP) after following 4 weeks of treatment</measure>
    <time_frame>Day 1 and day 28 of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Seating BP (systolic blood pressure (msSBP) and diastolic blood pressure (msDBP))measurements will be performed at trough(immediately prior to dosing at the clinic). Arterial BP readings will be made with an automated BP device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean siting pulse pressure after 4 weeks of treatment.</measure>
    <time_frame>Day 1 and day 28 of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Seating BP (systolic blood pressure (msSBP) and diastolic blood pressure (msDBP))measurements will be performed at trough(immediately prior to dosing at the clinic). Arterial BP readings will be made with an automated BP device.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Salt-sensitive Hypertension</condition>
  <arm_group>
    <arm_group_label>Valsartan followed by LCZ696</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: 4 weeks treatment with valsartan, 1-2 weeks wash-out, followed by period 2, 4 weeks treatment with LCZ696</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LCZ696 followed by Valsartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: 4 weeks treatment with LCZ696, 1-2 weeks wash-out, followed by period 2, 4 weeks treatment with valsartan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan</intervention_name>
    <description>Valsartan tablet once daily</description>
    <arm_group_label>Valsartan followed by LCZ696</arm_group_label>
    <arm_group_label>LCZ696 followed by Valsartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCZ696</intervention_name>
    <description>LCZ696 tablet once daily</description>
    <arm_group_label>Valsartan followed by LCZ696</arm_group_label>
    <arm_group_label>LCZ696 followed by Valsartan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Written informed consent must be obtained before any study assessment is performed.

          -  Males and females of non-childbearing potential and of legal age (at least 18 years
             or older as defined by local law).

          -  Asian patients with mild to moderate essential hypertension, untreated or currently
             taking antihypertensive therapy with up to two drugs.

        Key Exclusion Criteria:

          -  Women of child-bearing potential.

          -  History of angioedema, drug-related or otherwise

          -  History of hypersensitivity to LCZ696, valsartan, or drugs of similar chemical
             classes.

          -  Severe hypertension (grade 3 of WHO classification; msDBP ≥100 mmHg and/or msSBP ≥
             180 mmHg) at screening or at the end of the washout period.

          -  History or evidence of a secondary form of hypertension,

          -  Transient ischemic cerebral attack (TIA) during the 12 months prior to screening or
             any history of stroke.

          -  History of myocardial infarction, coronary bypass surgery or percutaneous coronary
             intervention (PCI) during 12 month prior to screening.

          -  Current or history of hypertensive retinopathy.

          -  Previous or current diagnosis of heart failure (NYHA Class II-IV).

          -  Clinically significant valvular heart disease at screening.

        Other protocol defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hong Kong</city>
        <state>Shatin, NT</state>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bucheon</city>
        <state>Gyeonggi-do</state>
        <zip>424-717</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koyang-si</city>
        <state>Gyeonggi-do</state>
        <zip>410-773</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>110 744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>152-703</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>168752</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <state>Taiwan, ROC</state>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Hong Kong</country>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 21, 2013</lastchanged_date>
  <firstreceived_date>August 30, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypertension, salt sensitivity, valsartan, LCZ696</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
